Brokerages Set Aptose Biosciences Inc. (NASDAQ:APTO) Target Price at $17.50

Aptose Biosciences Inc. (NASDAQ:APTOGet Free Report) (TSE:APS) has been assigned a consensus rating of “Buy” from the six analysts that are covering the company, reports. Six equities research analysts have rated the stock with a buy recommendation. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $17.50.

A number of equities research analysts have commented on APTO shares. Canaccord Genuity Group decreased their price target on Aptose Biosciences from $15.00 to $6.00 and set a “buy” rating on the stock in a report on Thursday, May 16th. HC Wainwright reaffirmed a “buy” rating and issued a $23.00 target price on shares of Aptose Biosciences in a report on Wednesday, March 27th. initiated coverage on Aptose Biosciences in a report on Thursday, June 6th. They issued a “hold” rating on the stock. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $5.00 target price on shares of Aptose Biosciences in a report on Wednesday, April 3rd.

View Our Latest Analysis on Aptose Biosciences

Institutional Investors Weigh In On Aptose Biosciences

An institutional investor recently raised its position in Aptose Biosciences stock. Annandale Capital LLC boosted its stake in shares of Aptose Biosciences Inc. (NASDAQ:APTOFree Report) (TSE:APS) by 40.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 74,666 shares of the biotechnology company’s stock after acquiring an additional 21,334 shares during the quarter. Annandale Capital LLC owned about 0.99% of Aptose Biosciences worth $209,000 as of its most recent SEC filing. Institutional investors own 26.62% of the company’s stock.

Aptose Biosciences Stock Up 4.5 %

Shares of APTO opened at $0.92 on Thursday. The business has a 50-day simple moving average of $1.18 and a two-hundred day simple moving average of $1.74. Aptose Biosciences has a 52 week low of $0.87 and a 52 week high of $6.31. The stock has a market cap of $16.63 million, a price-to-earnings ratio of -0.15 and a beta of 1.39.

Aptose Biosciences (NASDAQ:APTOGet Free Report) (TSE:APS) last issued its quarterly earnings results on Tuesday, May 14th. The biotechnology company reported ($0.73) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.09. On average, equities analysts anticipate that Aptose Biosciences will post -3.31 earnings per share for the current fiscal year.

Aptose Biosciences Company Profile

(Get Free Report

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

See Also

Analyst Recommendations for Aptose Biosciences (NASDAQ:APTO)

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with's FREE daily email newsletter.